11,640 reports of this reaction
1.5% of all DUPILUMAB reports
#18 most reported adverse reaction
DRY EYE is the #18 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 11,640 FDA adverse event reports linking DUPILUMAB to DRY EYE. This represents approximately 1.5% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience dry eye should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRY EYE is a less commonly reported adverse event for DUPILUMAB, but still significant enough to appear in the safety profile.
In addition to dry eye, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to dry eye in FDA adverse event reports:
DRY EYE has been reported as an adverse event in 11,640 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRY EYE accounts for approximately 1.5% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience dry eye while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.